The KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, bile duct cancer and thyroid cancer. The existence of KRAS mutations is often associated with a prognostic marker of drug response. For example, the KRAS mutation is considered a strong prognostic marker for drug response to tyrosine kinase inhibitors such as Gefitinib (Iressa) or Erlotinib (Tarceva). Recently, KRAS mutation is often detected in colorectal cancer and may be related to drug response to Cetuximab (Erbitux) or Panitumumab (Vectibix) used for colon cancer therapy. Therefore, KRAS mutation testing is necessary to determine drug resistance in patients with colorectal or lung cancer and will be useful for anticancer therapies.
PANAMutyper™ R KRAS
To detect KRAS mutations and determine their response to various treatments in colon cancer.
Cat. No. PNAR-1001
Other products
SimplyP Animal pathogens DNA/RNA Extraction Kit (BSC70M1)
This product provides a set of methods to rapidly extract...
EZ 10 spin column viral total RNA extraction kit (VT82112-50PREPS)
This kit allows for the simplified isolation of viral RNA...
PANA RealTyper™ HPV Screening Kit NAM-5001
For specific genotyping of two high-risk HPV types (16 and...
-86°C Ultra Freezer NU-99338J
Ultra-low temperature freezer